SEC Filing Summary: AspenBio Pharma, Inc. (Form 8-K)
Business Context and Reporting Period
This Form 8-K was filed by AspenBio Pharma, Inc. on January 28, 2009, reporting events that occurred on January 27, 2009. The filing addresses corporate governance matters regarding executive compensation. Note: The request metadata referenced "Riot Platforms, Inc."; however, the provided source text explicitly identifies the registrant as AspenBio Pharma, Inc.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity figures. The document focuses exclusively on the approval of stock option grants.
Material Changes and Executive Compensation
On January 27, 2009, the Board of Directors approved the customary annual grant of stock options under the 2002 Stock Incentive Plan. Key details include:
- Recipients: Principal Executive Officer Richard Donnelly and Principal Financial Officer Jeffrey McGonegal, along with other directors, officers, and employees.
- Grant Size: 50,000 shares of common stock options granted to each of the two named officers.
- Exercise Price: $1.33 per share (fair market value at market close on the grant date).
- Vesting Schedule: Annual vesting in arrears over three years.
- Expiration: Options expire in ten years.
Guidance, Outlook, and Risks
The filing text does not contain financial guidance, future outlook, management commentary on operations, or specific risk factors beyond the standard disclosure of the compensation arrangement.
Investor Verification Checklist
- Verify the total number of options granted to all employees and directors beyond the named officers.
- Confirm the current fair market value of the stock relative to the $1.33 exercise price to assess potential dilution or value.
- Review the full 2002 Stock Incentive Plan to understand remaining share availability and other terms.
- Check subsequent filings for any changes to the vesting schedule or exercise price.